semaglutide
Tirzepatide and GLP‑1 Agonists in the Golden Years: Myths Debunked
In 2023, 54 % of adults over 65 were prescribed a GLP-1 agonist for weight loss, signaling a new era of senior obesity care. The question is which drug offers the safest, most effective path for retirees. My experience shows tirzepatide’s dual-receptor action gives it a unique edge, but semaglutide